Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Branded drugs help Botox-maker Allergan beat profit estimates

Botox-maker Allergan Plc, which is in talks to be bought by Pfizer Inc, reported a better-than-expected quarterly profit on strong sales of high-margin branded drugs, its biggest business. Shares of Allergan, created from the merger of Actavis and Allergan, rose 1.4 percent to $313.50 in premarket trading on Wednesday. The Actavis-Allergan merger brought signature drugs […]

Read More »

OECD warns high-priced drugs are stretching health budgets

Specialty medicines for which pharmaceutical companies demand high prices are straining wealthy nations’ health budgets, the OECD said on Wednesday, with drugs accounting for some 20 percent of all health spending. Across the 33 OECD countries, pharmaceutical spending reached $800 billion in 2013, and new drugs and rising demand are likely to continue to push […]

Read More »

GSK aims to file up to 20 new drugs for approval by 2020

GlaxoSmithKline said on Tuesday it could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.   Seven of these products may reach the market before the end of decade, it added. Britain’s biggest drugmaker is trying […]

Read More »

GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment

Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)     LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 […]

Read More »

Still Yearning for Baxalta, Shire Snaps Up Dyax in $5.9 Billion Deal

Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]

Read More »

Vertex Pharma receives subpoena from Department of Justice

Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its “good laboratory practices” in a bioanalytical lab. Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Bioanalytical labs […]

Read More »

Regeneron Announces EU Approval of EYLEA (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

TARRYTOWN, N.Y., Oct. 30, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare has received European approval for EYLEA® (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV). Myopic CNV is an eye disease associated with high degrees of myopia (near-sightedness) and frequently affects people […]

Read More »

AbbVie projects double-digit annual earnings growth through 2020

AbbVie Inc (ABBV.N) reported higher quarterly sales and net income on Friday and forecast double-digit growth of earnings per share through 2020, putting the drugmaker in line to beat Wall Street’s current expectations. AbbVie, which was spun out of Abbott Laboratories in 2013, expects revenue of $37 billion in 2020, which is $5 billion more […]

Read More »

Sanofi Walks Away from a $613 Million Multiple Sclerosis Pact with Glenmark Pharma

PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals.   During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]

Read More »

FDA approves new Novartis dual combination bronchodilator Utibron Neohaler for patients with chronic obstructive pulmonary disease

– Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and improved lung function compared to placebo at 5 minutes after the first dose and throughout the dosing interval.1 It does not replace the use of a rescue inhaler – Utibron […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom